HUTCHMED (China) Limited ( (HK:0013) ) has shared an update.
HUTCHMED announced promising results from its SAVANNAH Phase II trial, showcasing high response rates for savolitinib combined with TAGRISSO® in MET-high lung cancer, offering a potential chemo-free treatment strategy. The company also reported long-term survival benefits from its Phase IIIb study of savolitinib in MET exon 14 NSCLC, and explored surufatinib as a maintenance therapy in small cell lung cancer, indicating strong potential for these treatments in improving patient outcomes.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery and development of targeted therapies for cancer and immunological diseases. The company is known for its innovative drug candidates, including savolitinib and surufatinib, which are being developed to address unmet medical needs in oncology.
YTD Price Performance: -2.13%
Average Trading Volume: 46,193
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.01B
For detailed information about 0013 stock, go to TipRanks’ Stock Analysis page.